Corrigendum: Improving therapy of pharmacoresistant epilepsies: The role of fenfluramine

Affiliations

¹ Department of Pediatrics, University of Perugia, Perugia, Italy.
² Pediatric Neurology and Muscular Diseases Unit, IRCCS "G. Gaslini" Institute, Genoa, Italy.
³ Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.

Published Erratum

Gianluca Dini et al. Front Pharmacol. 2023.

. 2023 Jan 5:13:1116575.

doi: 10.3389/fphar.2022.1116575. eCollection 2022.

¹ Department of Pediatrics, University of Perugia, Perugia, Italy.
² Pediatric Neurology and Muscular Diseases Unit, IRCCS "G. Gaslini" Institute, Genoa, Italy.
³ Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.

Abstract

[This corrects the article DOI: 10.3389/fphar.2022.832929.].

Keywords: Dravet syndrome; Lennox-Gastaut syndrome; anti-seizure medication (ASM); fenfluramine; pharmacoresistant epilepsy.

Improving Therapy of Pharmacoresistant Epilepsies: The Role of Fenfluramine.
Dini G, Tulli E, Dell'Isola GB, Mencaroni E, Di Cara G, Striano P, Verrotti A. Dini G, et al. Front Pharmacol. 2022 May 20;13:832929. doi: 10.3389/fphar.2022.832929. eCollection 2022. Front Pharmacol. 2022. PMID: 35668937 Free PMC article. Review.